Early-Onset Cancers: Investigating Etiology, Mechanisms, and Early Detection Strategies (RP1 Clinical Trials Optional)
National Institutes of Health
Classification and identifiers
- Solicitation number
- PAR-26-150
- Assistance listing (CFDA)
- 93.399
Amount
Amount not published by the funder
Who can apply
Other Eligible ApplicantsIndian/Native American Tribal Governments (Other than Federally Recognized);Eligible Agencies of the Federal Government;U.S. Territory or Possession;Regional Organizations;Non-domestic (non-U.S.) Entities (Foreign Institutions).
About this opportunity
Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) invites applications that investigate the etiology of sporadic non-hereditary early-onset cancers (EOCs: ages 18 to 49 years) and the underlying biological mechanisms that play a role in these cancers to inform prevention and control strategies. The proposed research is expected to advance the understanding of the unexplained rise of cancers in young adults. More specifically, studies should address one or more of the following: i) what modifiable exposures are driving the increase in the incidence of non-hereditary EOCs, and how do these factors vary by patient demographics? (ii) what biological mechanisms and host responses underly the increase in EOCs? and (iii) how can those at increased risk for dev...
Related opportunities
- Early-Stage Development of Informatics Technologies for Cancer Research and Management (U01 Clinical Trial Optional)National Institutes of HealthCloses Oct 2027Up to $300K
- Pancreatic Cancer Detection Consortium: Research Units (U01 Clinical Trial Optional)National Institutes of Health
- National Cancer Institute's Investigator-Initiated Early Phase Clinical Trials for Cancer Treatment and Diagnosis (R01 Clinical Trial Required)National Institutes of HealthCloses Jan 2027Up to $500K
- Exploratory Grants in Cancer Control (R21 Clinical Trial Optional)National Institutes of HealthCloses Sep 2028
- Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics (R01 Clinical Trial Optional)National Institutes of HealthCloses Jan 2027
- Cancer Prevention and Control Clinical Trials Grant Program (R01 Clinical Trial Required)National Institutes of HealthCloses Jan 2027